摘要
目的：探讨匹多莫德口服液治疗小儿支气管哮喘的临床疗效及其对机体免疫功能的影响。方法选择260例支气管哮喘患儿为研究病例，并采用随机数字表法分成两组，其中对照组130例采取常规治疗；观察组130例于常规治疗基础上加用匹多莫德口服液，对比临床疗效及免疫功能指标差异。结果观察组有效率为93．85％，与对照组的76．92％差异有统计学意义（χ^2＝7．86，P ＜0．05）。治疗前两组肺功能指标差异无统计学意义（P ＞0．05）。治疗后观察组 FVC（3．98±0．66）L、FEV1（3．07±0．29）L、PEF（3．58±0．42）L／min，较治疗前和对照组均有明显增加，差异有统计学意义（t ＝7．99、8．53、8．27、6．88、7．12、6．73，均P ＜0．05）。治疗前两组免疫功能各指标差异无统计学意义（P ＞0．05）。治疗后，观察组 CD3^＋（69．74±3．21）％、CD4^＋（42．95±4．76）％、CD4^＋／CD8^＋（1．38±0．44）％，较治疗前和对照组均有明显升高，CD8^＋（24．10±2．96）％，较治疗前和对照组均有明显降低，差异有统计学意义（t ＝8．43、7．55、7．54、7．51、6．74、6．55，均 P ＜0．05）。结论匹多莫德口服液治疗小儿支气管哮喘能够显著改善患儿的肺功能和免疫功能，疗效显著，应用价值高，可进行临床推广。
Objective To explore the clinical efficacy of pidotimod oral liquid in the treatment of children with bronchial asthma,and its effect on immune function.Methods 260 children of bronchial asthma were selected, and they were divided into two groups by random number table method.The control group was given routine treatment, while the observation group was given pidotimod oral liquid on the basis of conventional treatment.The clinical efficacy and immune function index were compared between the two groups.Results The effective rate of the observation group was 93.85%,which was higher than 76.92% of the control group,the difference was statistically significant （χ^2 =7.86,P 〈0.05）.There was no significant difference in lung function indexes between the two groups before treatment （P 〉0.05）.After treatment in the observation group,the FVC was （398 ±0.66）L,FEV1 was （307 ± 0.29）L,PEF was （3.58 ±0.42）L/min,and those were increased significantly compared with before treatment and the control group,the differences were statistically significant （t =7.99,853,8.27,6.88,7.12,6.73,all P 〈0.05）. There was no statistical difference in the indexes of the two groups before treatment （P 〉0.05）.After treatment,CD3^＋ was （6.974 ±3.21 ）%,CD4^＋ was （42.95 ±4.76 ）%,the ratio of CD4^＋ /CD8^＋ was （1.38 ±0.44）% of the observation group,which were significantly increased compared with pre -treatment and the control group,the CD8^＋ of the observation group was （24.10 ±2.96）,and it was obviously lower than pre -treatment and the control group,the differences were statistically significant （t =8.43,7.55,7.54,7.51,6.74,6.55,all P 〈0.05）.Conclusion Pidotimod oral liquid in treatment of bronchial asthma in children can significantly improve the pulmonary function and immune function of the children,the curative effect is remarkable,and the application value is high,which can carry on clinical promotion.
出处
《中国基层医药》
CAS
2016年第17期2702-2705,共4页
Chinese Journal of Primary Medicine and Pharmacy
